中国药物警戒 ›› 2026, Vol. 23 ›› Issue (7): 783-789.
DOI: 10.19803/j.1672-8629.20250676

• 基础与临床研究 • 上一篇    下一篇

猪苓多糖对化疗相关性肝损伤的保护作用研究

张媛媛1, 胡开永1, 张敏1, 刘敏1, 刘大会2, 李金鑫2, 王启维3, 彭佩1#, 黄茜1,*   

  1. 1荆楚理工学院化工与制药学院,湖北 荆门 448000;
    2湖北中医药大学药学院,湖北 武汉 430065;
    3南京医科大学第一临床医学院,江苏 南京 210000
  • 收稿日期:2025-09-20 出版日期:2026-07-15 发布日期:2026-07-16
  • 通讯作者: #为共同通信作者。*黄茜,女,博士,高级工程师,药理药效研究与新药研发。E-mail: hq@monyan.cn
  • 作者简介:张媛媛,女,硕士,初级工程师,药理药效研究。
  • 基金资助:
    国家重点研发计划(2023YFC3503804); 湖北省重点研发计划(2023BCB059); 湖北省中医药管理局中医药创新团队项目(ZY2025J002)

Protective effects of Polyporus umbellatus polysaccharides against chemotherapy-related liver injury

Zhang Yuanyuan1, Hu Kaiyong1, Zhang Min1, Liu Min1, Liu Dahui2, Li Jinxin2, Wang Qiwei3, Peng Pei1#, Huang Qian1,*   

  1. 1School of Chemical Engineering and Pharmacy, Jingchu University of Technology, Jingmen Hubei 448000, China;
    2School of Pharmacy, Hubei University of Chinese Medicine, Wuhan Hubei 430065, China;
    3The First School of Clinical Medicine, Nanjing University of Chinese Medicine, Nanjing Jiangsu 210000, China
  • Received:2025-09-20 Online:2026-07-15 Published:2026-07-16

摘要: 目的 探究猪苓多糖对小鼠化疗相关性肝损伤(CALI)的保护作用及其机制,评价其抗肿瘤活性。方法 选取雄性昆明小鼠,采用随机数字表分为正常对照组、模型组、猪苓多糖(100、200、400 mg·kg-1)组和阳性药组。模型组腹腔注射顺铂、奥沙利铂、顺铂和紫杉醇、顺铂和吉西他滨构建小鼠肝损伤模型,灌胃给予猪苓多糖及阳性药。测定各组小鼠血清中丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST),肝脏中丙二醛(MDA)、谷胱甘肽过氧化物酶(GSH-Px)、超氧化物歧化酶(T-SOD)的含量变化,考察其对CALI的保护作用。同时采用3-(4,5-二甲基噻唑-2)-2,5-二苯基四氮唑溴盐(MTT)法测定猪苓多糖在3个癌种(肝癌、结直肠癌、乳腺癌)9种不同细胞系上的抑制作用。结果 猪苓多糖可显著降低化疗药物引起的小鼠血清ALT和AST的升高(P<0.05),显著升高肝脏组织中T-SOD和GSH-Px酶活力,并降低MDA含量(P<0.05)。猪苓多糖对多种肿瘤细胞的增殖抑制均呈剂量和时间依赖性,特别是在肝癌Huh7(96 h的IC50为2.82 mg·mL-1)和MHCC97H(96 h的IC50为0.90 mg·mL-1)细胞中抑制效果显著。结论 猪苓多糖具有抑制肿瘤细胞增殖作用,可通过抗氧化机制保护CALI,其“双效合一”特性为CALI的防治提供参考。

关键词: 猪苓多糖, 肝损伤, 抗肿瘤, 化疗相关性肝损伤, 小鼠

Abstract: Objective To investigate the protective effect of Polyporus umbellatus polysaccharides against chemotherapy-associated liver injury (CALI) in mice and the underlying mechanism and to evaluate its antitumor activity. Methods Male Kunming mice were selected and randomly divided into four groups using a random number table method: a normal control group, model group, Polyporus umbellatus polysaccharides group(100, 200 and 400 mg·kg-1), and positive drug group. The model group was intraperitoneally injected with cisplatin, oxaliplatin, cisplatin combined with paclitaxel, and cisplatin combined with gemcitabine to establish models of mouse liver injury. Polyporus umbellatus polysaccharides and positive control drugs were administered via intragastric gavage. The protective effects against CALI were assessed by measuring serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities, as well as hepatic malondialdehyde (MDA) contents, glutathione peroxidase (GSH-Px) activities, and total superoxide dismutase (T-SOD) activities. Additionally, the inhibitory effect of Polyporus umbellatus polysaccharides on cancer cell proliferation was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide(MTT) assay across three cancer types and nine different cell lines (liver cancer, colorectal cancer, and breast cancer). Results Polyporus umbellatus Polysaccharides significantly attenuated the chemotherapeutic drug-induced increase in serum ALT and AST levels (P<0.05), and significantly enhanced the activities of T-SOD and GSH-Px while reducing the MDA content in liver tissues (P<0.05). The inhibitory effects of Polyporus umbellatus polysaccharides on the proliferation of tested cancer cells were both dose- and time-dependent, with particularly notable effects observed in hepatocellular carcinoma cells Huh7 (IC50=2.82 mg·mL-1 at 96 h) and MHCC97H (IC50=0.90 mg·mL-1 at 96 h). Conclusion These findings suggest that Polyporus umbellatus polysaccharides inhibit tumor cell proliferation and protect against CALI through an antioxidant mechanism. This dual-effect property offers a novel strategy for the prevention and treatment of CALI.

Key words: Polyporus umbellatus polysaccharides, Liver Injury, Anti-Tumor, Chemotherapy Associated Liver Injury(CALI), Mice

中图分类号: